Actively Recruiting
Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
Led by Xinqiao Hospital of Chongqing · Updated on 2025-07-14
96
Participants Needed
1
Research Sites
72 weeks
Total Duration
On this page
Sponsors
X
Xinqiao Hospital of Chongqing
Lead Sponsor
C
Chongqing Medical University
Collaborating Sponsor
AI-Summary
What this Trial Is About
1. To verify that thalidomide can increase the efficacy of cetuximab plus chemotherapy in the treatment of stage IV RAS and BRAF wild-type unresectable left colorectal cancer, which has important clinical significance and provides a basis for subsequent large-scale research and clinical application. 2. To evaluate the changes of cytokines and verify the effect of some cytokines on the efficacy of cetuximab +FOLFIRI, so as to provide a scientific basis for the subsequent precise therapy using cytokines antibodies.
CONDITIONS
Official Title
Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with RAS and BRAF wild-type stage IV unresectable left colorectal cancer confirmed by pathology and genetic testing
- Physical status of 0-2 on the performance scale
- Expected survival longer than 3 months
- Aged between 18 and 75 years
- No prior systemic chemotherapy
- No prior cetuximab treatment
- Normal liver, kidney, and bone marrow functions
- More than 4 weeks since last chemotherapy or targeted therapy
- Willing to participate, able to comply with study procedures, and sign informed consent
You will not qualify if you...
- Severe dysfunction of vital organs such as heart, liver, or kidney
- Presence of other malignant tumors
- Pregnant or breastfeeding women (pregnancy test required for women of childbearing age)
- Active acute or chronic infections
- History of drug allergy or allergic constitution
- Participation in other clinical trials
- Any other condition deemed unsuitable for study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
the second affiliated hospital of Army medical university
Chongqing, Chongqing Municipality, China, 400037
Actively Recruiting
Research Team
J
Jianguo Sun, doctor
CONTACT
R
rui kong, doctor
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here